Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
Could not agree more Cautious, I have no confidence in the board.
Anyway this might be of interest to those following the research work. Kathleen Schmainda is involved in a clinical trial. Interesting is no mention of IB, just MCW.
Here is the link. If you search for eaf223/gable and filter the results to the last week you get a few results with quite a lot of detail. It does fit in to one of the video presentations when they were discussing future work.
https://blog-ecog-acrin.org/now-enrolling-eaf223-gable-for-patients-with-glioblastoma/
The clinical trial reference is NCT06319027.
Financial results should be week after next, looking forward to seeing the figures.
Have a good weekend all
Shrek
Hello,
I agree the removal of the video was strange. No reason that I can see as it was all positive and had a lot of information that strengthened my assessment and I added as a result! No breach of confidentiality that I could see as I considered that.
The release of the letter to shareholders in a low key way was also odd. Previously done by RNS except for this one. Also missing is the follow up to the resubmission of PRDD. They have previously reported applications and decisions via RNS and/or twitter. Radio silence this time. The RNS regarding the admin error says that they will aim to resubmit by the following Friday, but not confirmed.
If I put my best tinfoil hat on, I may see a scenario in which it was in someone’s interest to restrict the flow of positive news to allow the share price to drift downward. Just a thought and making links that I cannot provenance, which is not good analysis. Yesterday’s interview had all the hallmarks of a rushed attempt to get the wheel on in my opinion, so likely they did not expect the reaction from PI’s.
Trek you described what has happened brilliantly. Thank you as it makes it very clear to me with a non financial background how much we have been shafted. All I would add is the other side of the coin regarding riding the coattails. This episode demonstrates the boards interests. Individual PI’s were obviously not part of the planning process and I cannot see that changing.
Shrek
The placing makes no business sense that I can see.
18th August last year was the announcement of the commercial agreement with GE Healthcare. No revenue was disclosed but it is logical that it will be generated.
Recently we have $200 k worth of grants that we know of. No idea of the funding from NIH etc but I would be amazed if the company wasn’t receiving any other grants. Last year we also were informed of a ‘step change’ in revenue. The messaging was positive.
So to raise £300 k the company trashes the mcap to &3 million and destroys investor confidence. I cannot make sense of it. I was taught to look for absence of the normal, presence of the abnormal and there are plenty of both here and it stinks.
Sorry for the rambling post.
Shrek
Evening all,
This is the link for the second grant. Again it is $50k.
https://ahwendowment.org/AHW/Health-Focused-Research/Developing-a-Novel-Gallium-Compound-for-the-Treatment-of-Metastatic-Breast-Cancer.htm
Full Project Name:
Developing a Novel Gallium Compound for the Treatment of Metastatic Breast Cancer
Principal Investigator:
Mona Al-Gizawiy, PhD, Biophysics
Award Amount:
$50,000
Award Date
January
2024
Project Duration:
12 months
The text of the company tweet from 12th November:
Congratulations to Dr. Mona Al-Gizawiy, PhD from the Schmainda Lab @MedicalCollege for being awarded not 1, but 2, @ahwendowment grants. The grants will fund the continued development and application of GaM, the oral agent under study in @IQAI_IB's phase 1 clinical trial.
So that’s $100k from AHW endowment. Plus the award for the expanded access program from the Musella Foundation of $100k.
Cheers
Shrek
Cynic here. Does anyone know the timeline for re submission of the rpdd? I have looked on the FDA site and not found it.
This paper is useful for Metformin and GaM as a combination as discussed in the video:
https://pubmed.ncbi.nlm.nih.gov/32391122/
This is some detail on one of the grants they have received:
Full Project Name:
Characterization of Response to Gallium Maltolate in Treatment-Resistant Glioblastoma
Principal Investigator:
Mona Al-Gizawiy, PhD, Biophysics
Co-Investigator:
Shama P Mirza, PhD, UW-Milwaukee Department of Chemistry & Biochemistry
Award Amount:
$50,000
Award Date
January
2024
Project Duration:
12 months
Here is the link:
https://ahwendowment.org/AHW/Health-Focused-Research/Characterization-of-Response-to-Gallium-Maltolate-in-Treatment-Resistant-Glioblastoma.htm
I found it a couple of days ago but got fed up with the share price shenanigans. Anyway there’s a fair bit of info in it. The links still work.
Have a good weekend all,
Cheers
Shrek
Hello Jimzi,
You have hit the nail on the head for me. We are not aware of any adverse news yet the mcap is now a touch over 5 million. That’s not support.
IB are busy and when I have time to research, what I find supports my view of the opportunity of this investment.
Cheers
Shrek
Apologies I haven’t been able to find the Update to phase 1 video. Looks like it was removed by IB.
However I did find this. It has the discussion around Metformin in combination which was in the phase 1.
Again lots of information and a 48 minute duration.
Here is the link :
https://youtu.be/amXeCGFkbSQ?si=lJ43Ez0H45WCzesq
Let’s see if it stays online.
Cheers
Shrek
Good morning all,
I found this video on the phase 1. Lots of information, need to watch it again.
https://youtu.be/2aGVwxK3cUM
Right back to work,
Cheers
Shrek
Good morning all
Here is the video link for the webinar:
https://youtu.be/wgoQ9Y6-5Rg?si=yQN4C4GUUrfFv2Mw
Shrek
I have checked previous RNS announcements and the letter to shareholders has been released via RNS since 2021. I fail to understand why they have changed now, especially given the disorderly selling. Surely it is in the company’s best interests to provide the information to the market via RNS not a post on Twitter?
Anyone any ideas ?
Thanks
Shrek